Departments of Health Policy (Dr Wiese, Mr Mitchel, and Drs Adgent, Patrick, and Grijalva), Vanderbilt University Medical Center, Nashville, TN.
Obstetrics and Gynecology (Dr Osmundson), Vanderbilt University Medical Center, Nashville, TN.
Am J Obstet Gynecol MFM. 2021 Nov;3(6):100475. doi: 10.1016/j.ajogmf.2021.100475. Epub 2021 Aug 26.
Opioid analgesics are commonly prescribed to women after cesarean delivery. There is a growing effort to prescribe opioids judiciously; however, the risk of serious opioid-related events associated with specific prescribing patterns after cesarean delivery remains unclear.
We examined the association between the dosage of the first opioid prescription filled after cesarean delivery and the risk of serious opioid-related events.
We identified opioid-naïve women with a cesarean delivery enrolled in Tennessee Medicaid (2007-2014). Pharmacy prescription fill data characterized opioids filled within 5 days after delivery. Patients were followed up from day 5 after delivery to the earliest of the following: serious opioid-related event (persistent opioid use, evidence of opioid use disorder [diagnosis or methadone or buprenorphine fill], overdose, or opioid-related death), non-opioid-related death, enrollment loss, or 365th day. We estimated the adjusted hazard ratios and 95% confidence intervals for the serious opioid-related event outcomes based on the dosage (morphine milligram equivalents) of the first filled opioid prescription, adjusting for baseline sociodemographic characteristics, delivery complications, multiple deliveries, comorbidities, and medication use. Secondary analyses examined the role of commonly prescribed opioid strengths and quantities.
The overall incidence rate of serious opioid-related events among women after cesarean delivery was 3.0 per 100 person-years. Compared with women who did not fill an opioid prescription, the rate of serious opioid-related events was higher among women who filled an opioid prescription, although only significantly higher among women who filled a total dosage of ≥100 morphine milligram equivalents (97.1% of opioid prescriptions). In the secondary analyses, women with a low prescribed daily opioid dosage and women with a low prescribed number of oxycodone (5 mg) tablets (<10 tablets) were not at increased risk of serious opioid-related events compared with women who did not fill an opioid prescription.
Opioid-naïve women who filled a postpartum opioid prescription at commonly prescribed doses after cesarean delivery had an increased risk of serious opioid-related events compared to women who did not fill a postpartum opioid prescription. Low opioid doses were not associated with a significant increase in the risk of serious opioid-related events.
阿片类镇痛药常用于剖宫产术后女性。目前正在努力谨慎开具阿片类药物,但剖宫产术后特定开具模式下与严重阿片类药物相关事件相关的风险仍不清楚。
我们研究了剖宫产术后首次开具的阿片类药物处方剂量与严重阿片类药物相关事件风险之间的关系。
我们确定了在田纳西州医疗补助计划中接受剖宫产术的阿片类药物初治女性(2007-2014 年)。药房处方数据描述了产后 5 天内开具的阿片类药物。从产后第 5 天开始,患者开始随访,直到以下最早时间:严重阿片类药物相关事件(持续阿片类药物使用、阿片类药物使用障碍的证据[诊断或美沙酮或丁丙诺啡的开具]、过量或阿片类药物相关死亡)、非阿片类药物相关死亡、失访或第 365 天。我们根据首次开具的阿片类药物处方的剂量(吗啡毫克当量),调整了基线社会人口统计学特征、分娩并发症、多次分娩、合并症和药物使用,估计了严重阿片类药物相关事件结局的调整后危害比和 95%置信区间。次要分析研究了常用阿片类药物强度和数量的作用。
剖宫产后女性严重阿片类药物相关事件的总体发生率为每 100 人年 3.0 例。与未开具阿片类药物处方的女性相比,开具阿片类药物处方的女性严重阿片类药物相关事件发生率较高,但仅在开具总剂量≥100 吗啡毫克当量(97.1%的阿片类药物处方)的女性中显著较高。在次要分析中,与未开具阿片类药物处方的女性相比,低规定日剂量的阿片类药物和低规定数量的羟考酮(5 毫克)片(<10 片)的女性严重阿片类药物相关事件风险没有增加。
与未开具产后阿片类药物处方的女性相比,剖宫产术后开具常见剂量产后阿片类药物处方的阿片类药物初治女性发生严重阿片类药物相关事件的风险增加。低阿片类药物剂量与严重阿片类药物相关事件风险的显著增加无关。